📊 BHIC Key Takeaways
Investment Thesis
BHIC demonstrates exceptional profitability with 64.8% gross margins and 21.3% net margins, supported by explosive 208.7% YoY revenue growth. The company maintains a fortress balance sheet with zero debt, $1.1M cash, and strong returns on equity (51.2%) and assets (42.4%), though concerns exist around modest operating cash flow conversion and micro-cap scale.
BHIC Strengths
- Exceptional gross margin of 64.8% indicates strong pricing power and operational efficiency
- Explosive 208.7% YoY revenue growth demonstrates significant market traction and scalability
- Outstanding profitability metrics with 21.3% net margin and 51.2% ROE
- Zero debt with positive stockholders' equity of $1.7M provides financial flexibility
- Massive interest coverage ratio of 1946x indicates no solvency risk
BHIC Risks
- Micro-cap company with only $4.1M revenue creates execution risk and limited track record at scale
- Operating cash flow of $272.9K significantly lags net income of $875.7K (31% conversion), raising quality of earnings concerns
- No insider buying activity in last 90 days could indicate limited management confidence
- Minimal current and quick ratio data unavailable, suggesting potential working capital management gaps
- Single period of strong growth requires validation of sustainability in subsequent reporting periods
Key Metrics to Watch
- Revenue growth sustainability and YoY acceleration/deceleration trends
- Operating cash flow conversion ratio relative to net income for quality of earnings
- Gross margin maintenance as revenue scales
- Customer concentration and retention metrics
- Working capital efficiency and cash conversion cycle
BHIC Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
BHIC Profitability Ratios
BHIC vs Technology Sector
How BioScience Health Innovations, Inc. compares to Technology sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
BHIC Balance Sheet & Liquidity
BHIC 5-Year Financial Trend
5-Year Trend Summary: BioScience Health Innovations, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.01 indicates the company is currently unprofitable.
BHIC Growth Metrics (YoY)
BHIC Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $573.0K | -$8.8K | $0.00 |
| Q2 2025 | $384.2K | $20.8K | $0.00 |
| Q1 2025 | $277.6K | -$53.4K | $0.00 |
| Q3 2024 | $192.2K | -$53.4K | $0.00 |
| Q2 2024 | $69.5K | $20.8K | N/A |
| Q1 2024 | $32.3K | -$53.4K | N/A |
| Q3 2023 | $19.7K | -$1.9K | N/A |
| Q2 2023 | N/A | -$1.9K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
BHIC Capital Allocation
BHIC SEC Filings
Access official SEC EDGAR filings for BioScience Health Innovations, Inc. (CIK: 0001784440)
📋 Recent SEC Filings
❓ Frequently Asked Questions about BHIC
What is the AI rating for BHIC?
BioScience Health Innovations, Inc. (BHIC) has an AI rating of BUY with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are BHIC's key strengths?
Exceptional gross margin of 64.8% indicates strong pricing power and operational efficiency. Explosive 208.7% YoY revenue growth demonstrates significant market traction and scalability.
What are the risks of investing in BHIC?
Micro-cap company with only $4.1M revenue creates execution risk and limited track record at scale. Operating cash flow of $272.9K significantly lags net income of $875.7K (31% conversion), raising quality of earnings concerns.
What is BHIC's revenue and growth?
BioScience Health Innovations, Inc. reported revenue of $4.1M.
Does BHIC pay dividends?
BioScience Health Innovations, Inc. does not currently pay dividends.
Where can I find BHIC SEC filings?
Official SEC filings for BioScience Health Innovations, Inc. (CIK: 0001784440) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is BHIC's EPS?
BioScience Health Innovations, Inc. has a diluted EPS of $0.08.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.